Myomo Inc. Common Stock (MYO)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Graham-style investor, I start with whether the business earns money and has a durable advantage. Myomo sells MyoPro, a wearable myoelectric orthosis for people with neuromuscular disorders. The product is interesting, but the numbers show a company still searching for profitability. Revenue has grown: fiscal FY2025, the year ended 2025-12-31, was $40.9 million, up from $32.6 million in fiscal FY2024, the year ended 2024-12-31, and $19.2 million in fiscal FY2023, the year ended 2023-12-31. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $11.7 million versus $9.7 million in fiscal Q2 2025, the quarter ended 2025-06-30. That is real top-line progress. But the bottom line remains weak. Fiscal Q2 2026 net income was -$4.0 million; fiscal Q1 2026, the quarter ended 2026-03-31, was -$3.0 million; fiscal FY2025 net income was -$15.6 million, worse than -$6.2 million in fiscal FY2024. Trailing free cash flow is -$9.1 million, a -17.8% FCF yield on the $51.1 million market cap as calculated by FairStock. The balance sheet carries a debt-to-equity ratio of 3.44, and FairStock's Altman Z-Score of -3.35 and Piotroski F-Score of 3/9 suggest financial stress. The Lynch category is none because it lost money in each of the last four years. At the 2026-10-13 close of $1.29, the FairStock-calculated negative P/E of -3.79 and P/B of 8.60 do not give me a margin of safety. The FairStock Score is 22/100. I would need evidence of durable profitability and cash generation before calling this a bargain. Until then, it is a speculative medical-device story, not a proven compounding business.

In plain English: Myomo makes wearable robotic arm braces for people with muscle weakness or paralysis. The business is growing revenue, but it has lost money for years and burned cash, so it does not look financially strong. At $1.29 a share on 2026-10-13, the price looks speculative rather than clearly cheap because there are no profits to support it.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer